{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"Abbreviation","name":"MITC"},{"type":"Abbreviation","name":"MITO"},{"type":"Abbreviation","name":"MITO-C"},{"type":"Abbreviation","name":"MTC"},{"type":"ForeignBrandName","name":"Mitocin-C"},{"type":"ForeignBrandName","name":"Mito-Medac"},{"type":"ForeignBrandName","name":"Mitolem"},{"type":"ForeignBrandName","name":"Ametycine"},{"type":"ChemicalStructureName","name":"[1aS-(1a alpha,8beta,8a alpha,8b alpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione"},{"type":"ObsoleteName","name":"Mitozytrex"},{"type":"Synonym","name":"mitomycin-X"},{"type":"ForeignBrandName","name":"Mutamycine"},{"type":"ChemicalStructureName","name":"(1aS,8S,8aR,8bS)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione"},{"type":"Synonym","name":"mitomycine C"},{"type":"ObsoleteName","name":"Mutamycin"},{"type":"LexicalVariant","name":"mitomycin-C"},{"type":"CodeName","name":"NCI-C04706"},{"type":"Synonym","name":"mitomycin C"},{"type":"USBrandName","name":"Jelmyto"},{"type":"ChemicalStructureName","name":"(1aS,8S,8aR,8bS)-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione"},{"type":"CASRegistryName","name":"50-07-7"},{"type":"ForeignBrandName","name":"Mitocin"},{"type":"USBrandName","name":"Mitosol"}],"definition":{"html":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. Bioreduced mitomycin generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Preferentially toxic to hypoxic cells, mitomycin also inhibits RNA and protein synthesis at high concentrations.","text":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. Bioreduced mitomycin generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Preferentially toxic to hypoxic cells, mitomycin also inhibits RNA and protein synthesis at high concentrations."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/mitomycin","text":"Mitomycin"},"nciConceptId":"C1820","nciConceptName":"Mitomycin","termId":42674,"name":"mitomycin","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"mitomycin"},{"aliases":[{"type":"Synonym","name":"mitomycin C SR hydrogel formulation UGN-103"},{"type":"Synonym","name":"SR MMC hydrogel formulation UGN-103"},{"type":"CodeName","name":"UGN 103"},{"type":"CodeName","name":"UGN-103"},{"type":"CodeName","name":"UGN103"}],"definition":{"html":"A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing a lyophilized form of the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon intravesical instillation of the SR MMC hydrogel formulation UGN-103, the liquid converts into gel form and conforms to the bladder wall, allowing MMC to be deposited locally in the bladder to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures, and undergoes transition to a water-soluble gel at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for bladder cancer.","text":"A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing a lyophilized form of the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon intravesical instillation of the SR MMC hydrogel formulation UGN-103, the liquid converts into gel form and conforms to the bladder wall, allowing MMC to be deposited locally in the bladder to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures, and undergoes transition to a water-soluble gel at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for bladder cancer."},"drugInfoSummaryLink":null,"nciConceptId":"C212939","nciConceptName":"Sustained-release Mitomycin C Hydrogel Formulation UGN-103","termId":817287,"name":"sustained-release mitomycin C hydrogel formulation UGN-103","firstLetter":"s","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"sustained-release-mitomycin-c-hydrogel-formulation-ugn-103"}],"links":null}